Prestige Consumer Healthcare Inc. (NYSE: PBH) reported robust financial results for its third quarter and first nine months ending December 31, 2023. With revenues reaching $282.7 million in Q3, up 2.6% from the previous year, and diluted EPS at $1.06, a 2.2% increase, the company demonstrated steady growth.
CEO Ron Lombardi attributed the positive results to the company’s leading portfolio of brands and strategic marketing investments, which drove solid revenue growth of nearly 3%. Notably, the Eye & Ear Care category in North America and the Hydralyte® brand in the International segment contributed significantly to revenue growth.
For the first nine months of fiscal 2024, reported revenues totaled $848.4 million, representing a 0.8% increase compared to the same period last year. Despite challenges such as lower Women’s Health category sales and the strategic exit of private label revenues, the company saw solid performance in its International segment, particularly in the Gastrointestinal category.
The company’s strong financial performance translated into improved cash flow and earnings growth, with net cash provided by operating activities reaching $71.5 million in Q3 and $182.0 million for the first nine months of fiscal 2024.
With a net debt position of approximately $1.1 billion and a reduced leverage ratio of 2.9x, Prestige Consumer Healthcare remains financially resilient. The company’s disciplined capital deployment resulted in a $65 million reduction in debt during the quarter.
Looking ahead, Lombardi announced an updated earnings outlook for fiscal 2024, raising expectations based on the strong Q3 performance. The company anticipates revenues of $1,135 to $1,140 million for the fiscal year, driven by its diverse brand portfolio and continued strategic investments.
Prestige Consumer Healthcare’s solid performance in Q3 reflects its resilience and strategic focus, positioning the company for continued growth and value creation for shareholders in the coming quarters.
